The Effectiveness of β-blockers in Women With Congestive Heart Failure

Keyhan, Golyar; Chen, Shun-Fu; Pilote, Louise

doi:10.1007/s11606-007-0197-1

Cited by 10 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for ACE‐I, the trial data on BBL is mirrored in “real life” patients, too. A large‐scale analysis from community‐treated patients in Canada found a significant survival benefit with beta‐blocker use in both sexes [72]. Sensitivity analyses adjusting for selection bias confirmed that the survival benefit was similar in men and women.…”

Section: Survival Benefit From Individual Classes Of Drugs According mentioning

confidence: 94%

Influence of Sex on Treatment and Outcome in Chronic Heart Failure

Frankenstein

Clark

Ribeiro

2011

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYThe population is aging, the prevalence of heart failure increases with age, and on average women live longer than men. There is evidence for sex-specific effects of individual, guideline-recommended drugs used for treatment of chronic heart failure. Women are underrepresented in most clinical trials and only a minority of drug applications to regulatory authorities have included sex analyses. The present review focuses on the potential female survival benefit in heart failure, the influence of sex on medical treatment in a broader sense, and the potential benefit to be derived from guideline recommended treatment and common adjunctive heart failure medication.

show abstract

Section: Survival Benefit From Individual Classes Of Drugs According mentioning

confidence: 94%

Influence of Sex on Treatment and Outcome in Chronic Heart Failure

Frankenstein

Clark

Ribeiro

2011

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…In addition, women are more likely to have a high median serum digoxin level, and this may explain the higher incidence of digitalis toxicity in women [27]. Data derived from heart failure studies have revealed that other commonly used drugs, such as beta-blockers (e.g., for patients with MS), angiotensin-converting enzyme (ACE) inhibitors (e.g., for patients with dilated LV), and diuretics (for symptomatic volume overload), were equally effective in women and men [28,29]. It is worth noting that ACE inhibitors and angiotensin receptor blockers (ARBs) are absolutely contraindicated during pregnancy and lactation because of the risk of fetopathy and neonatal renal impairment [30].…”

Section: Management Drugsmentioning

confidence: 99%

Valvular heart diseases in women

Youssef

2021

Egypt Heart J

View full text Add to dashboard Cite

Background Valvular heart disease is a common health problem affecting both sexes and all age groups. Almost all guidelines are based on studies that mainly involved male patients. Main body The features of valvular heart diseases in women were essentially derived from small observational studies. These studies have shown that women differ from men in terms of the type of valve disease, pathology affecting the valve, perception of symptoms, parameters measured in echocardiography, response to drugs, surgical techniques, and postoperative outcomes. This review was conducted to demonstrate the uniqueness of valvular heart diseases in women and raise awareness about the need for sex-based randomized study designs to provide a piece of proper evidence to support suitable sex-based guidelines and recommendations. Moreover, it briefly describes the effects of pregnancy on women with valvular heart diseases and the impact of the latter on the course of pregnancy and the well-being of the mother and fetus. Conclusion Valvular heart diseases in women are different from those in men. Sex-based guidelines for managing valvular heart diseases are needed.

show abstract

“…In the sex-stratified analysis, beta-blockers conferred similar survival benefits in men and women; no sex by treatment interaction was found. 17 Another study of patients with HF discharged with beta-blocker therapy showed that patients with reduced LVEF had a significantly lower risk-adjusted mortality. In contrast, both men and women with preserved LVEF derived no benefit from beta-blocker therapy.…”

Section: Womenmentioning

confidence: 99%